| Description | RGH-5526 is a novel antihypertensive drug. It causes an increase in hypothalamic norepinephrine (NA) turnover (utilization), and the increase in hypothalamic noradrenergic neuron activity may lead to a decrease in peripheral sympathetic nerve activity, resulting in a significant reduction in blood pressure. |
| In vivo | Following prolonged treatment, RGH-5526 does not influence the hypothalamic monoamine oxidase (MAO)-activity. Results show a sharp (61%) decrease the hypothalamic Noradrenaline (NA) level 2 h after the administration of 10 mg/kg of RGH-5526, and this effect lasts for 4 to 6 h. It is shown that RGH-5526 exerts a greater NA lowering effect in the hypothalamus than in the periphery[1]. |
| Synonyms | GYKI-11679 |
| molecular weight | 335.4 |
| Molecular formula | C16H25N5O3 |
| CAS | 69579-13-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Huszti Z, et al. Influence on turnover and level of hypothalamic noradrenaline by a new antihypertensive agent (GYKI 11679). J Neurochem. 1981 Nov;37(5):1272-81. |